By Edie Stringfellow, Director of Diversity & Inclusion, MassBio “March is Women’s History Month and I wanted to use the occasion to focus on women in venture capital (VC) and their impact on investments in…
“Looking back over 2018, it is clear that the year was one of contrasts for biopharma companies. The medtech sector was fairly placid in comparison. For drug developers, areas of disappointment included the failure of…
“The past year proved to be a big one for the U.S. Food and Drug Administration (FDA) and the approval of novel drugs. Over the course of 2018, the FDA approved 59 different novel drugs that range for the…
